腎・心血管障害における細胞内分子機構の解明とその治療法の開発

  • 石澤 啓介
    徳島大学大学院ヘルスバイオサイエンス研究部医薬品機能生化学

書誌事項

タイトル別名
  • Drug Discovery for Improvement of Chronic Kidney Disease and Cardiovascular Disease
  • ジン シンケッカン ショウガイ ニ オケル サイボウ ナイブンシ キコウ ノ カイメイ ト ソノ チリョウホウ ノ カイハツ

この論文をさがす

抄録

  Chronic kidney disease (CKD) has been increasingly recognized as a major public health problem in the world. Recent studies have showed that CKD is an independent risk factor for the occurrence of cardiovascular disease (CVD). Reactive oxygen species (ROS), generated by reduction-oxidation actions, have been generated by reduction-oxidation actions, recognized as the important chemical mediators that regulate signal transduction in various cells including vascular smooth muscle cells (VSMC) and mesangial cells (MC). It has been showed that increase in ROS generation may relate to a risk for CVD and CKD. In addition, ROS mediate activation of mitogen-activated protein (MAP) kinases, extracellular signal-regulated kinase 1/2, c-Jun N-terminal kinase, p38, and big MAP kinase 1, in various cells leading to change in gene expressions. Control of the oxidative stress and ROS-mediated alterations of signaling molecules including MAP kinases may provide new therapeutic strategy against CKD and CVD. In this review, we summarize mainly our data regarding the pharmacological effects of renin-angiotensin-aldosterone system blockers, bioflavonoids and adiponectin in VSMC and MC. Also we review the data on a possible new class drug against oxidative stress to improve CKD and CVD.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 131 (9), 1347-1352, 2011-09-01

    公益社団法人 日本薬学会

参考文献 (38)*注記

もっと見る

詳細情報

問題の指摘

ページトップへ